Wedbush Rates Rocket Pharmaceuticals Outperform with $32 Target
Wedbush initiates coverage on Rocket Pharmaceuticals (RCKT) with an Outperform rating and a $32 price target, signaling strong growth potential.
Topic
stock target
A collection of 3 issues
Northland Analyst Sets $175 Target for AMD
Northland analyst Gus Richard maintains a $175 price target for AMD, focusing on AI strategy and server CPU performance. Discover AMD's growth potential.
Wedbush Boosts Apple Stock Target to $325
Wedbush analysts increase Apple's stock target by $25, affirming an 'outperform' rating. Discover why Apple remains a strong investment choice.